Citius Pharmaceuticals Inc

Citius Pharmaceuticals Inc. a late-stage pharmaceutical company engages in the development and commercialization of critical care products focusing on oncology products anti-infectives products in adjunct cancer care prescription products and stem cell therapy. It is developing five proprietary products comprising I/ONTAK an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma; Mino-Lok an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Halo-Lido a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; Mino-Wrap a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford New Jersey.